Werewolf Change In Cash from 2010 to 2024

HOWL Stock  USD 1.59  0.02  1.27%   
Werewolf Therapeutics Change In Cash yearly trend continues to be quite stable with very little volatility. The value of Change In Cash is projected to decrease to about 23.9 M. From the period between 2010 and 2024, Werewolf Therapeutics, Change In Cash regression line of its data series had sample variance of 577.7 T and sample variance of 577.7 T. View All Fundamentals
 
Change In Cash  
First Reported
2010-12-31
Previous Quarter
25 M
Current Value
23.9 M
Quarterly Volatility
24 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Werewolf Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Werewolf Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 4.7 M, Depreciation And Amortization of 951.3 K or Interest Expense of 3.3 M, as well as many indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0 or PTB Ratio of 1.3. Werewolf financial statements analysis is a perfect complement when working with Werewolf Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

Latest Werewolf Therapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Werewolf Therapeutics over the last few years. It is Werewolf Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Werewolf Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Pretty Stable
   Change In Cash   
       Timeline  

Werewolf Change In Cash Regression Statistics

Arithmetic Mean18,827,656
Coefficient Of Variation127.66
Mean Deviation15,252,695
Median12,101,000
Standard Deviation24,034,603
Sample Variance577.7T
Range103M
R-Value0.24
Mean Square Error586.1T
R-Squared0.06
Significance0.39
Slope1,292,900
Total Sum of Squares8087.3T

Werewolf Change In Cash History

202423.9 M
202325 M
2022-28.3 M
202166.1 M
202074.7 M

About Werewolf Therapeutics Financial Statements

Werewolf Therapeutics investors utilize fundamental indicators, such as Change In Cash, to predict how Werewolf Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Cash25 M23.9 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
0.082
Quarterly Revenue Growth
(0.86)
Return On Assets
(0.26)
Return On Equity
(0.62)
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.